Ethical Guidelines 9/24/15. Controlled Substance Update Texas Nurse Prac66oners Annual Conference Objec6ves
|
|
- Wesley Sherman
- 5 years ago
- Views:
Transcription
1 Texas Nurse Prac66oners Annual Conference 2015 Kimberly H. Oas, MSN, APRN, FNP- BC Jan Zdanuk, DNP, APRN, FNP- BC, FAANP Ethical Guidelines Speakers report no rela6onships with business or industry that would pose a conflict of interest Objec6ves Review regulatory statutes and issues specific to NP prac6ce in Texas to include BON requirements resul6ng from SB406 in 2013 and any current issues Define key prac6ce implica6ons and responsibili6es of the NP in the management of pain pa6ents 1
2 Objec6ves Iden6fy treatment goals, obstacles to efficacy and Best Prac6ce regarding pain management, including the use of controlled substances Explore medica6on classifica6on, key prescrip6ve medica6ons and prac6ce guidelines Prescrip(on Access in Texas (PAT) database Authorized users can search the last 365- days worth of prescrip6on dispensing history for Schedule II V controlled substances, 24- hours a day, seven- days a week, including: Pa6ent prescrip6on history and Provider s own prescribing history hbps:// login.aspx Prescrip(on Access in Texas (PAT) PAT is a secured, online monitoring program, which assists Texas health care and law enforcement professionals in iden6fying poten6al prescrip6on drug abuse. PAT provides controlled substance dispensing history to medical prac66oners, board inves6gators and law enforcement professionals. 2
3 What you need to prescribe in Texas RN License q 2 years APRN License q 2 years (effec6ve with your renewal) DPS Registra6on yearly if prescribing controlled substances DEA Registra6on q 3 years if prescribing controlled substances What can we prescribe by state? TEXAS Schedule 3, 3N, 4, 5 Prescribe & Administer APRNs outside of a hospital facility or qualified hospice provider sejng cannot currently prescribe schedule 2 CS 2 opium, morphine, codeine, hydromorphone (Dilaudid), methadone, meperidine (Demerol), hydrocodone (Vicodin) CS 2N amphetamine, methamphetamine, nabilone Mid- Level Prac66oners Authoriza6on by State. (2015). Retrieved from Mid- Level Prac66oners Authoriza6on by State. Accessed April 19, 2015 hbp:// DEA Controlled Substance Schedules Sch Descrip(on Examples I No currently accepted medical use in Heroin, LSD, marijauna, peyote, the US.; high poten6al for abuse methaqualone, Ecstasy II III High poten(al for abuse, which may Hydromorphene, methadone, meperidine, lead to severe psychological or physical oxycodone, fentanyl, morphine, opium, and dependence codeine, amphetamine, methamphetamine, methylphenidate, hydrocodone,hcp* Poten6al for abuse, which may lead to 90 mg codeine per dose, buprenorphine, moderate or low physical dependence benzphetamine, phendimetrazine, ketamine, or high psychological dependence anabolic steroids IV Low poten6al for abuse Alprazolam, carisoprodol, clonazepm, clorazepate, diazepam, lorazepam, midazolam, temazepam, triazolam, tramadol* V Low poten6al for abuse Cough prepara6ons containing 200 mg codeine per 100 ml or per 100 g 3
4 Hospital Based Care Sec6on (b- 1)(1) of the Medical Prac6ce Act relates to prescribing for pa6ents while in a hospital. An APRN or PA, may issue a Schedule II prescrip6on as long as it is filled at the hospital pharmacy for a LOS of at least 24 hours or is receiving services in the emergency dept. Accessed September 20, 2015 from hbps:// If a schedule II is to be filled anywhere outside the hospital, the prescrip6on must be completed by a licensed physician. Accessed September 20, 2015 from hbps:// faq_prac6ce_aprn.asp Hospice Care Sec6on (b- 1)(2) of the Medical Prac6ce Act allows for APRN and PA to write Schedule II prescrip6ons as part of the plan of care for the treatment of a person who has executed a wriben cer6fica6on of a terminal illness, has elected to receive hospice care, and is receiving hospice treatment from a qualified hospice provider. Accessed September 20, 2015 from hbps:// 4
5 Nurse Anesthe6sts and Nurse Midwives have excep6ons to this ruling (Chapter 157 of Texas Medical Prac6ce Act). DPS registra6on has been transferred over to the Texas Board of Pharmacy effec(ve Sept. 1, 2016 (SB195, 2015) All ac6ve CSR were renewed August 20, 2015 and will expire August 31, 2016 For New Applicants un(l Sept. 1, 2016 DPS Registra6on Required in TEXAS for CS hbp:// 77A- 78A.pdf Ini(al: $25. Renewal: $25. Late Fee: Addi(onal $50 Criminal background check each year Consent to Inspect: Signature of the applicant further grants the director/ designee, the right to enter and inspect premises. Records are required to be kept (Texas Controlled Substances Act). 5
6 DEA Registra6on Ini6al Renewal Cost: $731. for 3 years TEXAS APRN Contact Hours required effec6ve January 1, 2015 with every licensure cycle 3 Contact Hours on prescribing controlled substances (if prescribing controlled substances) 5 Contact Hours in pharmacotherapeu6cs 2 Contact Hours in Nursing Jurisprudence and Ethics every 3 rd renewal cycle (Eff ) 2 Contact Hours on Geriatric care of older adults every licensure cycle (if applicable) 20 Contact Hours for APRN Renewal Nursing Jurisprudence and Ethics All day Workshop: Protec6ng Your Pa6ents and Your Prac6ce 7CNE $109. TX BON Online Interac6ve Course: Nursing Regula6ons for Safe Prac6ce 2CNE $25. TX BON Online Texas Nursing and Jurisprudence and Ethics Course. 2 CE. $19. 6ll 12/31/ TX15 Online Texas Nursing and Jurisprudence and Ethics. 2 CE. $ Express.com Texas BON hbp:/// 6
7 Roles and Responsibili6es of Provider Consider pa6ent needs, type of pain Old Carts Onset, Loca6on, Dura6on, Character, Aggrava6ng factors, Relieving factors, Timing, Severity Diagnosis; Prognosis Co- exis6ng factors Roles and Responsibili6es of Provider Drug to drug interac6ons Assess (kidney and renal func6on ) Adherence/Aberrant behaviors Misuse, Abuse/Addic6on, Diversion Consider OTC s, herbals and supplements (Acetaminophen etc.) Roles and Responsibili6es of Provider Follow prescribing guidelines *Controlled Substances Agreement/Contract Monitor prescrip6on usage (UDT or saliva swab) Safe storage; no sharing; proper disposal 7
8 Roles and Responsibili6es of Pa6ent Ac6ve vs. passive role in treatment plan Pt. must be involved in determina)on of posi6ve treatment outcome Quality of Life is defined by the Pa6ent! What does Chronic Pain Pa6ent need to Know? 100% pain allevia6on may not be possible Decrease pain be realis6c Improve func6on be realis6c Returning to normal can mean different things to different people Provider hopping is no guarantee of success; may be detrimental to their health 8
9 Goal Sejng Up Front With Pain Pa6ents Provides framework for treatment decisions Allows for mutually agreed upon expecta6ons Involve significant others and caregivers Document Goals, progress, achievements, func6onal status, physical and psychological interven6ons and referrals Barriers to Goal Abainment Pt. knowledge, health literacy, educa6on, impairment (physical or emo6onal) Pt. biases, stress, depression, mo6va6on, fear of future failure, past failures, or provider mistrust Provider unwilling to relinquish control or do referrals Signs of Troubled Rela6onship Pt. or Aborney request for records Considera)ons: For every 1 death from Prescrip6on drugs: 10 Hospital Admissions 32 ER Visits 130 prescrip6ve users who misuse / abuse 825 non medical users Substance Abuse and Mental Health Services Administra6on Drug Abuse Warning Network
10 Risk Stra6fica6on Low Risk No family history, no past or current substance use disorders No major depression, anxiety, or other psycho- social disorders Risk Stra6fica6on Moderate Risk ( Yellow Flag Cau6on!) History of Substance Abuse Family History of problema6c drug abuse Past or current psychopathology Not ac6vely addicted Risk Stra6fica6on High Risk ( Red Flags) Ac6ve Substance Abuse Major Untreated or undertreated psychopathology Ac6vely addicted: Criminal history of drug possession or diversion Chou, E ( 2009) Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Non Cancer Pain. The journal of Pain 10 (2) 10
11 When Termina6on should be a considera6on Non- compliance/non- adherence Missed appointments or abruptly leaving Drug seeking behavior Threatening or verbal abuse, hos6lity, aggression or violent behavior toward Provider or Staff Provider or Pt. feels no longer a therapeu6c rela6onship Pt. requires treatment outside of exper6se Termina6ng the Provider/Pa6ent Rela6onship *Controlled Substance Agreement/Contract If signed and witnessed up front and pt. violates there are grounds for termina6on of rela6onship by following guidelines Pt. sent a registered leber which must be signed for; Given a 30 day no6ce to find a new provider; covered for emergencies for 30 days; do not fill any RX for controlled substances Do not re- establish care Proper no6fica6on via registered mail with 30 day no6ce is NOT abandonment of pa6ent. It is not necessary to give reason. Ending the pa6ent- physician rela6onship. (2013). Retrieved from hbp:// assn.org/ama/pub/physician- resources/legal- topics/pa6ent- physician- rela6onship- topics/ending- pa6ent- physician- rela6onship. page 11
12 Do Not Tolerate abuse or violence Discern involving law enforcement Renew Pt. rela6onship once terminated Reminder Keep interac6ons on Social Media professional at all 6mes, especially with medical personnel and pa6ents Best Prac6ces published by the AAN to treat chronic noncancer pain (Franklin, 2014) Establish Diagnosis; Document physical and psychological interven6ons Track pain and func6onal status at every visit Document daily MED in mg/dl using online opioid calculator at every visit hbp://agencymeddirectors.wa.gov/mobile.html Access prescrip6on drug monitoring program (PDMP) at a first visit for opioids and PRN Best Prac6ce Screen for past/current substance abuse, severe depression, anxiety, and PTSD prior to ini6a6on of chronic opioid analgesic therapy (COAT) Use urine drug tes6ng (UDT) prior to chronic opioid analgesic therapy (COAT) and PRN Use a Pa6ent Treatment Agreement at ini6a6on of COAT and annually 12
13 Best Prac6ce Don t use concomitant seda6ve- hypno6cs or benzodiazepines Avoid escala6ng doses above mg/d MED unless sustained meaningful improvement in pain and func6onal status is not abained and not without consulta6on with a Pain Management Specialist (Franklin, 2014) Reality 50 million Americans suffer from chronic pain 4 out of 10 don t get adequate relief 80% seek chronic pain relief in primary care sejngs Shortage of Pain management Specialist 1 for every 21,000 pa6ents Schram & Kohn, Chronic pain program in a Primary Care Sejng. Prac6cal Pain Managment2015. Challenge & Opportunity. Leverage Non Pharm op6ons to include: yoga, relaxa6on, mindfulness; CBT 13
14 Comprehensive Pain Management Program Outcomes 108 programs evaluated Sta6s6cal significance at 6 months and 1 year Supports interdisciplinary care for chronic pain management Domains Assessed Pain Severity Emo6onal Distress Interference of pain on func6on Perceived Control of Pain Treatment helpfulness Number of hours res6ng Key treatment Components Individualized behavioral medicine ( CBT) Physical Therapy Aqua6c Therapy Occupa6onal Therapy Group Educa6on Group relaxa6on Proceedings, Baylor University Medical Center,
15 Best Prac6ce Know your pa6ent Leverage mul6faceted management Be realis6c Seek assistance when appropriate NP Prac)ce Resources State Texas Nurse Prac66oners Prac6ce Commibee (TNP) Texas Board of Nursing (BON) Texas Nurses Associa6on APRN Commibee (TNA) Texas Medical Board Na6onal American Associa6on of Nurse Prac66oners (AANP) Ques(ons 15
16 References Chou, E. (2009). Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. The Journal of Pain, 10(2). Ending the pa6ent- physician rela6onship. (2013). Retrieved from hbp:// assn.org/ama/pub/physician- resources/legal- topics/pa6ent- physician- rela6onship- topics/ending- pa6ent- physician- rela6onship.page. Franklin, G. (2014). Opioids for chronic noncancer pain: A posi6on paper of the American Academy of Neurology. Neurology, 83; Mid- Level Prac66oners Authoriza6on by State. (2015). Retrieved from Mid- Level Prac66oners Authoriza6on by State. Accessed March 8, References Na6onal Plan and Provider Enumerator System. (2015). Retrieved from hbp:// Accessed March 8, Opioid Dose Calculator. (2015). Retrieved from hbp://agencymeddirectors.wa.gov/mobile.html Accessed April 20, Start a Self- Query. (2015). Retrieved from hbp:// pract/hasareportbeenfiledonyou.jsp. Accessed March 8, Substance Abuse and Mental Health Services Administra6on Drug Abuse Warning Network. (2011). Na6onal Es6mates of Drug Related Emergency Department Visits. HHS Publica)on No , Dawn Series, D- 35(August 2011). Texas Board of Nursing. (2015). APRN Frequently asked ques6ons. Retrieved September 20, 2015 hbps:// faq_prac6ce_aprn.asp We have enjoyed presen6ng this Let s get together again soon! April 22-24, 2016 at Hyab Hill Country Resort and Spa, San Antonio, Texas and Sept. 8-11, 2016 at the Grand Hyab San Antonio, Texas (River walk) ENJOY THE TNP CONFERENCE! 16
PAIN. Texas Nurse Prac,,oner s Pharmacology and Primary care Conference Narco,cs Update April 24-25, Ethical Guidelines.
Texas Nurse Prac,,oner s Pharmacology and Primary care Conference April 24-25, 2015 Ethical Guidelines Speakers report no rela,onships with business or industry that would pose a conflict of interest.
More informationPROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH
San Diego State University Environmental Health and Safety PROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH SUMMARY A number of substances or chemicals regulated by
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationPolicy and Issuance Patient Age Group: ( ) N/A ( ) All Ages ( ) Newborns ( X) Pediatric ( X) Adult
Applies To: Ambulatory Services Responsible Department: Ambulatory Admin Revised: 02/2018 Title: Controlled Substance Prescription Processing, Security Policy and Issuance Patient Age Group: ( ) N/A (
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationTechnician Tutorial: Scheduled Drugs
(Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationOpioid Pain Contracts: A Resident Driven Quality Improvement Project
Opioid Pain Contracts: A Resident Driven Quality Improvement Project A Response to the Opioid Epidemic Dr. Phillip Knouse Dr. Victoria Montgomery Disclosure None Objectives Discuss the current Opioid Epidemic
More informationPrac%cing and Thriving in an Unlicensed State
Prac%cing and Thriving in an Unlicensed State WHY? What can you do? How do you prac%ce? Don t you want to be in a licensed state? Naturo- what?? FEAR...the discouraging factor Legal Ramifica%ons Disregard
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationMark W. Caverly, Chief Liaison and Policy Section
DEA Issues: An Update Harold Rogers National Prescription Drug Monitoring Meeting Meeting September 24 25, 2009 Mark W. Caverly, Chief Liaison and Policy Section Prescription Drug Abuse Prescription Drug
More information10/26/15. Perspec'ves on maternal opioid use and abuse. Dr. Rita J. Nutt. Our Expectation. Harsh Realities
10/26/15 Perspec'ves on maternal opioid use and abuse Dr. Rita J. Nutt Our Expectation Harsh Realities 1 Opioid Abuse and Dependence Statistics, 2013 4.5 million people in the US current non- medical users
More informationSULLIVAN COUNTY Drug Abuse Prevention Task Force
SULLIVAN COUNTY Drug Abuse Prevention Task Force Joseph A. Todora LMSW, Commissioner Sullivan County Division of Health ans Family Servies 17 Community Lane Liberty, NY 12754 MISSION: The mission of the
More informationControlled Substances in the Lab Environment STACI MEADE JAMES PITCHER
Controlled Substances in the Lab Environment STACI MEADE JAMES PITCHER Who are we? James Pitcher, CPA Senior Internal Auditor, UIHC Anesthesia College of Dentistry Staci Meade, CPA, MAC Internal Auditor,
More informationDr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force
Dr. Smith Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force 1 1 How We Got Here 2 The Epidemic 3 4 San Diego Death Diaries
More informationApril 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director
More informationASPMN Conference Baltimore, Maryland
ASPMN Conference Baltimore, Maryland Prescribing Controlled Substances Managing Risk and Optimizing Outcomes September 13, 2012 Tracey Fremd, NP Tracey Fremd Consulting, Inc. Most Common Uses for Controlled
More informationState, District, or Territory Criteria for Mandatory Enrol ment or Query of PDMP
State, District, or Territory Alabama Arizona Arkansas Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate, the applicant shall have a current
More informationDepartment of Emergency Office of Research. Shannon McNabb, MA, MPH Clinical Research Manager January 2017
Department of Emergency Medicine Office of Research Shannon McNabb, MA, MPH Clinical Research Manager January 2017 EM Study Tracking System UPDATED ON: 12/5/2016 TOTAL 68 Grants Submitted, Award Pending
More informationPrescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder
Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM Preventative Education: Substance Use Disorder Misuse of prescription pain relievers is, after marijuana use, the second most common form of
More informationPain Management. 24th Annual Family Medicine Potpourri. Dr Amy Yeatman NeuroTeam at Bellin Health
24th Annual Family Medicine Potpourri Pain Management Dr Amy Yeatman NeuroTeam at Bellin Health President NeuroTeam Advisory Board Instructor for the World Ins:tute of Pain Instructor for American Society
More informationIbogaine treatment for opioid dependence in New Zealand: A 12- month post- treatment follow- up observa>onal study
Ibogaine treatment for opioid dependence in New Zealand: A 12- month post- treatment follow- up observa>onal study Geoff Noller, PhD Substance Use and Policy Analysis In associa>on with Researching NZ
More informationLouisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationRole of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx
Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationMissouri Guidelines for the Use of Controlled Substances for the Treatment of Pain
Substances for the Treatment of Pain Effective January 2007, the Board of Healing Arts appointed a Task Force to review the current statutes, rules and guidelines regarding the treatment of pain. This
More informationOregon s PDMP: An epidemiological assist tool
Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section
More informationTop 10 narcotic pain pills
Top 10 narcotic pain pills Click to go to the item or just scroll down the page. Doctors Respond to FDA Panel Recommendations FDA Considers Banning Popular Prescription Pain Medications and. Top 10 Natural
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationOpioids: Public Health Crisis Local Solutions: National Epidemic
Opioids: Public Health Crisis Local Solutions: National Epidemic Nancy McGraw, LCSW, MBA Public Health Director Sullivan County Public Health Services 50 Community Lane Liberty, NY 12754 Luis Alvarez,
More informationANNUAL REPORT
ANNUAL REPORT - 2015 New Hampshire Prescription Drug Monitoring Program Report for July 1, 2014 June 30, 2015 Published October 2015 Table of Contents Executive Summary... 3-4 NH PDMP Background Information
More informationTo have loved and lost: A group for students who have lost a loved one
To have loved and lost: A group for students who have lost a loved one 1 Background Informa;on A bereaved person is grieving the loss of someone (or something) he or she valued Loss can nega;vely impact
More informationProposed Revision to Med (i)
Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and
More informationChemo Brain and Fa.gue Chemotherapy Related Cogni:ve Impairment Chemotherapy Related Fa:gue. Alok Pant, MD Northwestern Medicine
Chemo Brain and Fa.gue Chemotherapy Related Cogni:ve Impairment Chemotherapy Related Fa:gue Alok Pant, MD Northwestern Medicine Chemotherapy Related Cogni.ve Changes Agen:on Concentra:on Learning Memory
More informationCOUNTY OF SAN DIEGO. Opioid Update
COUNTY OF SAN DIEGO Opioid Update Linda Bridgeman Smith, DUI & Prevention Services Manager Health & Human Services Agency, Behavioral Health Services Co-chair, Prescription Drug Abuse Task Force 1 HEADLINES
More informationTennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationRecrea&onal Therapy. Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi<ee on Accredita&on of Recrea&onal Therapy Educa&on
Recrea&onal Therapy Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi
More informationVermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
More informationLearning Objec1ves. Study Design Considera1ons in Clinical Pharmacy
9/28/15 Study Design Considera1ons in Clinical Pharmacy Ludmila Bakhireva, MD, PhD, MPH Pree Sarangarm, PharmD, BCPS Learning Objec1ves Describe the features, advantages and disadvantages of the observa1onal
More informationExempted Codeine Products:
Exempted Codeine Products: Perceptions, principles, & optimizing practice CPhM PDP Jan. 14, 2016 Jamie Falk, PharmD Faculty/Presenter Disclosure Faculty: Jamie Falk Rela,onships with commercial interests:
More informationSubstance Use and Addiction. Presentation for Physicians and Other Health Care Providers JOHN HARSANY JR. M.D. F.A.S.A.M.
Substance Use and Addiction Presentation for Physicians and Other Health Care Providers JOHN HARSANY JR. M.D. F.A.S.A.M. Addiction Medicine The specialty of medicine devoted to diagnosis, treatment, prevention,
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More informationMedica8on Assisted Treatment (MAT) in Jails and Community- Based SeDngs
Medica8on Assisted Treatment (MAT) in Jails and Community- Based SeDngs Lisa Ramirez, Lead Program Specialist, Texas Department of State Health Services, Mental Health and Substance Abuse Division Rebecca
More informationPrescription Drug Abuse: Colorado and Nationwide
Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?
More informationOhio Council on Family Relations What s Up With Opiates? 2.0. BY: Philip Atkins, PhD, LICDC-CS,OCPC Executive Director Mental Health & Recovery Board
Ohio Council on Family Relations What s Up With Opiates? 2.0 BY: Philip Atkins, PhD, LICDC-CS,OCPC Executive Director Mental Health & Recovery Board Who We Are. www.oacbha.org Setting the Context Where
More informationA Bill Regular Session, 2015 SENATE BILL 717
Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator
More informationRhode Island. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationMichael M. Miller, MD, FASAM, FAPA
Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the
More informationOpioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM
Western Occupational Health Conference September 14, 2012 Opioid - Use & Misuse Scott Levy, MD MPH FACOEM Steven Feinberg, MD, MPH Disclosure Information Western Occupational Health Conference 2012 Steven
More informationPatient Agreement for the use of Opioid Medications
today s date Patient Name date of birth Patient Agreement for the use of Opioid Medications The purpose of this agreement is to give you information about the medications that may be part of your treatment
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationInterventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?
Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference? Richard C. Dart, MD, PhD Executive Director of RADARS System, Denver, Colorado Professor, University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Alaska Requires adoption of regulations that provide that a practitioner query the PDMP prior to dispensing, prescribing, or administering a Sch. II or III controlled substance; query is not required for
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationPrescription Drug Impact in the Workplace
Prescription Drug Impact in the Workplace Iowa Drugged Driving Summit September 27, 2016 Tess Benham, Sr. Program Manager, National Safety Council 1 Drug Overdoses now cause more deaths than car crashes.
More informationDemerol 50 mg vs hydrocodone
Demerol 50 mg vs hydrocodone The Borg System is 100 % Demerol 50 mg vs hydrocodone 7-2-2016 What's the difference between the effects of Demerol and. Oxycodone 15-20 mg (orally) Vicodin (hydrocodone).
More informationIdentification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities
Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationPRESCRIPTION DRUG MONITORING PROGRAM
PRESCRIPTION DRUG MONITORING PROGRAM ST. LOUIS COUNTY Q2 2017 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6 Dispensation
More informationHarold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD
Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD National Epidemic Highlighted numerous studies/media reports State Epidemic Highlighted
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationOregon Prescription Drug Monitoring Program
Oregon Prescription Drug Monitoring Program 2013 Annual Report to the PDMP Advisory Commission PUBLIC HEALTH DIVISION Prescription Drug Monitoring Program Oregon Prescription Drug Monitoring Program 2013
More informationLesson 5 - Regulations and Standards Assignment Answer Key
Assignment 1 Critical Thinking Question Lesson 5 - Regulations and Standards Assignment Answer Key 1. Should a health care organization punish individuals for reporting prescription errors that they made
More informationFrom Wikipedia, the free encyclopedia
1 of 6 11/24/2010 11:43 PM From Wikipedia, the free encyclopedia The regulation of therapeutic goods, that is drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationCreate More Effec,ve Doctor Appointments. More than 100,ps you can start using today! By: Shani Weber, M.S.
Create More Effec,ve Doctor Appointments More than 100,ps you can start using today! By: Shani Weber, M.S. How Do You Get the Help You Need? Build a great medical team Have reasonable expecta6ons Collect
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationManaging Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.
Managing Narcotics on Workers Comp Claims Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. October 21, 2014 Outline Rationale Scope list drug list Recommended
More informationLearning Objec1ves. Study Design Strategies. Cohort Studies 9/28/15
9/28/15 Learning Objec1ves Describe the features, advantages and disadvantages of the observa1onal study designs Explain why the overall study design is important when evalua1ng studies & applying their
More informationEngage and Empower Pa.ents with Interac.ve Technology. Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012
Engage and Empower Pa.ents with Interac.ve Technology Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012 NAHAM - Pa.ent Access Services 2 Pa%ent Access Services
More informationArkansas Prescription Monitoring Program
Arkansas Prescription Monitoring Program ONE YEAR UPDATE Scott Pace, Pharm.D., Esq. Special Thanks Thanks to Denise Robertson at the Arkansas Department of Health for supplying the PMP data for this presentation
More informationPrescription Drug Abuse Task Force Rx Report Card
San Diego County Prescription Drug Abuse Task Force 2016 Rx Report Card October 2016 Key Measures of Prescription Drug and Heroin Problems in San Diego County. Visit www.sandiegorxabusetaskforce.org for
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationLegal Issues in Opioid Prescribing
Legal Issues in Opioid Prescribing Joanne L. Martin, J.D. Legal Counsel Mayo Clinic Rochester, Mn 2015 MFMER slide-1 Conflict of Interest I have no relevant financial relationships to disclose I will not
More informationDAWN. In 2009, nearly 4.6 million emergency
Drug Abuse Warning Network The DAWN Report December 28, 2010 Highlights of the 2009 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits In Brief In 2009, there were nearly
More informationIn 2009, nearly 4.6 million emergency
Drug Abuse Warning Network The DAWN Report December 28, 2010 Highlights of the 2009 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits In Brief In 2009, there were nearly
More informationThe Latest Prescription Trends for Controlled Prescription Drugs
The Latest Prescription Trends for Controlled Prescription Drugs September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner
More informationADDICTION OPIOID ADDICTION
ADDICTION OPIOID ADDICTION DRUG ADDICTION Take Home Points 1 Drug addic=on is impossible to avoid in your prac=ce 2 Huge burden on economy, families, society 3 Drug addic=on is Treatable drug addicts deserve
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationAnnual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use
Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use Report of the Government of: Reporting Year: Completed on (date): Please return completed questionnaire to: arq@unodc.org
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationWest Virginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile West Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
More informationLAI: Linee guida ed esperienze internazionali
LAI: Linee guida ed esperienze internazionali LAI: Guidelines and interna5onal experience PM Llorca CHU Clermont-Ferrand EA 7280 Université Clermont Auvergne Disclosures Advisory board: Allergan, Jansen,
More informationEthics and Boundaries
Ethics and Boundaries Jim Seckman, MAC, CACII, CCS What are the defining characteris@cs of a profession? A body of knowledge A special group of skills Addresses a special problem Tes@ng for admission Lifelong
More informationMichigan Automated Prescription System
MAPS Michigan Automated Prescription System Accuracy of Data Edits applied. Most at 95% Two full time technicians. Two part time students. Full time analyst One shared tech and PT programmer. Data uploads
More informationOpioid Prescribing for Acute Pain
Patient Reference Guide Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Quality standards outline what high-quality care looks like. They focus on conditions or topics where
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationCOMBATING THE OPIATE CRISIS IN OHIO THROUGH COMPREHENSIVE RESPONSE 2018 HOUSING OHIO CONFERENCE APRIL 9 TH, Objectives: Key Terms
COMBATING THE OPIATE CRISIS IN OHIO THROUGH COMPREHENSIVE RESPONSE 2018 HOUSING OHIO CONFERENCE APRIL 9 TH, 2018 2 Objectives: qreview names of different types of opioids qidentify the signs and symptoms
More informationThe Drug Testing Process. Employer or Practice
Disclosures Clinical Professor, Jefferson Medical College BOD MROCC [Medical Review Officer Certification Council] BOD National Sleep Foundation BOD POEMS [Pennsylvania Occupational & Environmental Medicine
More informationOpioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016
1 Opioid Abuse in Iowa Rx to Heroin Iowa Governor s Office of Drug Control Policy January 2016 Why Is This Important? 2 3 National Rx Painkiller Trends CDC, 2013 4 National Rx-Heroin Trends NIH, 2015 5
More informationPARTICIPANT GENERAL INFORMATION
PARTICIPANT GENERAL INFORMATION Instructions: Please complete entire form (print) First name: Last Name: Other names used: Street address: City/State/Zip: County: Region: East TN Middle West Social Security
More informationLUNCH AND LEARN. January 8, CE Activity Information & Accreditation
LUNCH AND LEARN Pharmacy Law: The Ins and Outs of Controlled Substances January 8, 2016 Featured Speaker: Joseph J. Bogdan, Pharm.D., R.Ph., J.D. Pharmacist Attorney Lisle, Illinois 1 CE Activity Information
More information